PMID- 27177330
OWN - NLM
STAT- MEDLINE
DCOM- 20180122
LR  - 20211204
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 31
DP  - 2016 Aug 2
TI  - mTOR: An attractive therapeutic target for osteosarcoma?
PG  - 50805-50813
LID - 10.18632/oncotarget.9305 [doi]
AB  - Osteosarcoma (OS) is a common primary malignant bone tumor with high morbidity 
      and mortality in children and young adults. How to improve poor prognosis of OS 
      due to resistance to chemotherapy remains a challenge. Recently, growing findings 
      show activation of mammalian target of rapamycin (mTOR), is associated with OS 
      cell growth, proliferation, metastasis. Targeting mTOR may be a promising 
      therapeutic approach for treating OS. This review summarizes the roles of mTOR 
      pathway in OS and present research status of mTOR inhibitors in the context of 
      OS. In addition, we have attempted to discuss how to design a better treatment 
      project for OS by combining mTOR inhibitor with other drugs.
FAU - Ding, Liu
AU  - Ding L
AD  - Department of Orthopaedics, The Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Congwei, Liu
AU  - Congwei L
AD  - Department of Orthopaedics, The Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Bei, Qing
AU  - Bei Q
AD  - Department of Thoracic Surgery, The Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
FAU - Tao, Yang
AU  - Tao Y
AD  - Department of Otolaryngology, Head and Neck Surgery, The second Xiangya Hospital 
      of Central South University, Changsha, Hunan, China.
FAU - Ruiguo, Wang
AU  - Ruiguo W
AD  - Clinical Medicine for Eight-Year-Program, Xiangya School of Medicine, Central 
      South University, Changsha, Hunan, China.
FAU - Heze, Yu
AU  - Heze Y
AD  - Clinical Medicine for Eight-Year-Program, Xiangya School of Medicine, Central 
      South University, Changsha, Hunan, China.
FAU - Bo, Dou
AU  - Bo D
AD  - Clinical Medicine for Eight-Year-Program, Xiangya School of Medicine, Central 
      South University, Changsha, Hunan, China.
FAU - Zhihong, Li
AU  - Zhihong L
AD  - Department of Orthopaedics, The Second Xiangya Hospital of Central South 
      University, Changsha, Hunan, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Antineoplastic Agents/chemistry
MH  - Apoptosis
MH  - Autophagy
MH  - Bone Neoplasms/diagnosis/*drug therapy/*metabolism
MH  - Cell Enlargement
MH  - Cell Proliferation
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Osteosarcoma/diagnosis/*drug therapy/*metabolism
MH  - Prognosis
MH  - TOR Serine-Threonine Kinases/*metabolism
PMC - PMC5226621
OTO - NOTNLM
OT  - apoptosis
OT  - autophagy
OT  - mTOR
OT  - osteosarcoma
OT  - target
COIS- The authors declare that they have no competing interests.
EDAT- 2016/05/14 06:00
MHDA- 2018/01/23 06:00
PMCR- 2016/08/02
CRDT- 2016/05/14 06:00
PHST- 2016/01/14 00:00 [received]
PHST- 2016/05/05 00:00 [accepted]
PHST- 2016/05/14 06:00 [pubmed]
PHST- 2018/01/23 06:00 [medline]
PHST- 2016/05/14 06:00 [entrez]
PHST- 2016/08/02 00:00 [pmc-release]
AID - 9305 [pii]
AID - 10.18632/oncotarget.9305 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Aug 2;7(31):50805-50813. doi: 10.18632/oncotarget.9305.